1. Postpartum Depression

2. Program Overview

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Distinguishing PPD From "Baby Blues"

5. Postpartum Anxiety

6. Barriers to Care

7. Inadequate Treatment of PPD

8. Impact of PPD on Mother and Child

9. Screening for PPD

10. Edinburgh Postnatal Depression Scale

11. Patient Health Questionnaire-2

12. Screening for PPD: Recommendations

13. Risk for PPD: Gene-Environment Interaction

14. Potential Endocrine Influences on PPD

15. Treatment of PPD

16. Emerging Treatments for PPD: Estradiol

17. Emerging Therapy: Targeting the GABAA Receptor

18. Phase 3 Study of Brexanolone in Moderate PPD

19. Phase 3 Study of Brexanolone in Severe PPD

20. Moderate PPD: Common Presentation

21. Severe PPD: Common Presentation

22. Assessing Potential for Harm: Distinguishing PPD From Postpartum Psychosis

23. Conclusions

24. Abbreviations

25. Abbreviations (cont)